The New England Journal of Medicine June 21, 2025

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes

Julio Rosenstock, Stanley H. Hsia, Luis Nevárez Ruiz, et al.

Bottom Line

In adults with early type 2 diabetes inadequately controlled with diet and exercise, the novel once-daily oral non-peptide GLP-1 receptor agonist orforglipron significantly reduced HbA1c and body weight over 40 weeks compared to placebo.

Key Findings

1. At week 40, the estimated mean change from baseline in HbA1c was -1.24% (3 mg), -1.47% (12 mg), and -1.48% (36 mg), compared to -0.41% for placebo (estimated mean differences of -0.83 to -1.07 percentage points; P<0.001 for all).

2. Mean HbA1c at week 40 dropped to between 6.5% and 6.7% across the orforglipron dose groups.

3. Body weight was significantly reduced by week 40 (a key secondary endpoint), with percent changes of -4.5% (3 mg), -5.8% (12 mg), and -7.6% (36 mg) compared to -1.7% with placebo.

4. Permanent discontinuation due to adverse events occurred in 4.4% to 7.8% of participants receiving orforglipron versus 1.4% of those receiving placebo.

5. The most common adverse events were mild-to-moderate gastrointestinal events (nausea, diarrhea), which predominantly occurred during the dose-escalation phase.

Study Design

Design

RCT

Double-Blind

Sample

559

Patients

Duration

40 wk

Median

Setting

Multicenter

Population Adults with early type 2 diabetes and inadequate glycemic control (baseline HbA1c 7.0-9.5%, mean 8.0%) with diet and exercise alone, who are naive to other antihyperglycemic therapies.

Intervention Once-daily oral orforglipron monotherapy (at maintenance doses of 3 mg, 12 mg, or 36 mg).

Comparator Once-daily oral placebo.

Outcome Change from baseline in glycated hemoglobin (HbA1c) level at week 40.

Study Limitations

• Relatively short follow-up duration (40 weeks) precludes the assessment of long-term durability, cardiovascular outcomes, and long-term safety.

• Excluded patients on background antihyperglycemic therapies, limiting generalizability to patients with more advanced type 2 diabetes.

• Higher rate of gastrointestinal adverse events and discontinuations compared to placebo, particularly during dose escalation.

• The trial was not designed or powered to assess cardiovascular event reduction.

Clinical Significance

Orforglipron provides an effective, once-daily oral GLP-1 option without the strict fasting, fluid, or post-dose waiting restrictions that limit the convenience of oral semaglutide. For patients with early type 2 diabetes, particularly those averse to injections, it delivers robust glycemic control and meaningful weight loss, representing a highly accessible early-line therapy that may broaden the clinical utilization and adherence of the GLP-1 receptor agonist class.

Historical Context

Injectable GLP-1 receptor agonists have revolutionized the management of type 2 diabetes and obesity, but their use is constrained by patient reluctance to use needles, the high costs and manufacturing complexities of peptides, and cold-chain supply requirements. While oral semaglutide was the first oral GLP-1 RA, its peptide nature requires strict adherence to fasting and fluid intake rules to ensure absorption. Orforglipron was developed as a non-peptide, small-molecule GLP-1 receptor agonist to overcome these barriers, offering simple oral administration independent of food and water restrictions. The phase 3 ACHIEVE clinical program (for type 2 diabetes) and the parallel ATTAIN program (for obesity) evaluate its definitive efficacy. ACHIEVE-1 established its utility as a highly effective early monotherapy for type 2 diabetes, with significant concomitant weight loss benefits.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

How does the biochemical structure of orforglipron as a non-peptide small molecule provide a major pharmacokinetic and administrative advantage over existing oral peptide-based GLP-1 receptor agonists like oral semaglutide?

Key Response

Oral semaglutide is a peptide that requires co-formulation with a SNAC absorption enhancer and must be taken on a strictly empty stomach with a small amount of water to prevent rapid proteolytic degradation and allow absorption. In contrast, orforglipron is a small molecule that is not subject to degradation by gastrointestinal peptidases, allowing it to be absorbed like a traditional oral drug without strict fasting or fluid restrictions, significantly improving patient convenience and adherence.

Resident

A patient with newly diagnosed type 2 diabetes and a BMI of 34 kg/m2 is hesitant to start injectable medications and feels unable to adhere to the strict fasting schedules required for oral semaglutide. How would the availability of orforglipron influence your management strategy for this patient?

Key Response

Orforglipron offers a highly efficacious oral alternative for HbA1c lowering and weight loss without the strict fasting administration constraints of oral semaglutide. This makes it an ideal early escalation therapy to achieve weight-centric diabetes management goals for patients with needle phobia or lifestyle barriers to complex dosing regimens, allowing residents to effectively target both glycemic control and adiposity without sacrificing adherence.

Fellow

Non-peptide small molecule GLP-1 receptor agonists can exhibit biased agonism compared to endogenous GLP-1 or peptide analogues. How might the specific G-protein versus beta-arrestin recruitment profile of an agent like orforglipron theoretically impact its long-term efficacy and tolerability profile?

Key Response

Biased agonism can affect how a receptor internalizes and desensitizes. A small molecule that preferentially favors G-protein signaling (which drives cAMP generation for insulin secretion) while minimizing beta-arrestin recruitment (which drives receptor internalization) might reduce receptor downregulation. This could theoretically prolong the drug's efficacy and alter the gastrointestinal side effect profile compared to traditional peptide agonists, a key consideration for long-term incretin therapy.

Attending

Given the profound global supply chain shortages and high manufacturing costs of injectable GLP-1 receptor agonists, how does the emergence of easily synthesized oral small-molecule GLP-1 agonists like orforglipron fundamentally shift our population health approach to managing early type 2 diabetes?

Key Response

Small molecule drugs are significantly cheaper and easier to manufacture at scale using standard chemical synthesis, unlike complex recombinant peptides that require specialized biomanufacturing facilities. An effective oral non-peptide GLP-1 RA democratizes access to highly effective incretin therapies, overcoming current supply constraints and potentially allowing health systems to adopt weight-centric diabetes management as a global standard of care rather than a luxury for well-resourced populations.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

In the Phase 2 ACHIEVE-1 trial, various dose-escalation regimens of orforglipron were utilized to mitigate gastrointestinal adverse events. From a methodological standpoint, how does the statistical modeling of optimal titration schemes in Phase 2 trials influence the power and intention-to-treat analysis of subsequent Phase 3 trials?

Key Response

Optimizing titration is critical for GLP-1 RAs to balance efficacy and tolerability. Researchers must analyze tolerability curves and PK/PD modeling from Phase 2 to design Phase 3 titration schedules that minimize dropout from GI side effects. If a titration scheme is poorly calibrated and leads to high attrition rates, it compromises the intention-to-treat analysis, reduces statistical power, and introduces survivorship bias, making accurate dose-finding in Phase 2 the linchpin of successful Phase 3 outcomes.

Journal Editor

As a peer reviewer evaluating the ACHIEVE-1 trial, how would you critique the study design regarding the absence of an active comparator arm (such as oral semaglutide or an SGLT2 inhibitor), and what implications does this have for interpreting its clinical utility?

Key Response

While placebo-controlled trials establish baseline efficacy and safety, the T2D therapeutic landscape is crowded. A rigorous reviewer would flag that without a head-to-head active comparator, it is difficult to determine if this new agent provides superior, non-inferior, or inferior glycemic control and weight loss compared to existing standard-of-care oral agents. This limits the ability of clinicians to place orforglipron accurately within the current treatment algorithm.

Guideline Committee

Current ADA/EASD guidelines emphasize early use of GLP-1 RAs with high efficacy for weight loss in T2D patients with comorbid obesity, but often retain metformin as initial therapy due to cost and access. If Phase 3 data for orforglipron confirms the safety, efficacy, and manufacturability scalability seen in ACHIEVE-1, how might this alter the strength of recommendation for initial oral therapy?

Key Response

Guidelines currently balance the superior cardioprotective and weight loss benefits of GLP-1 RAs against their high cost, supply issues, and injectable administration (or strict oral fasting rules). If a cheap, highly effective, easily administered oral GLP-1 RA becomes available, it could compel the ADA/EASD to strongly recommend incretin-based therapy over metformin as universal first-line treatment, shifting the entire paradigm toward early weight-centric management regardless of socioeconomic constraints.

Clinical Landscape

Noteworthy Related Trials

2019

PIONEER 1 Trial

n = 703 · JAMA

Tested

Oral semaglutide (3, 7, or 14 mg daily)

Population

Adults with type 2 diabetes managed with diet and exercise

Comparator

Placebo

Endpoint

Change in HbA1c from baseline to week 26

Key result: Oral semaglutide significantly reduced HbA1c and body weight compared to placebo.

2021

SURPASS-1 Trial

n = 478 · Lancet

Tested

Tirzepatide (5, 10, or 15 mg once weekly)

Population

Adults with early type 2 diabetes inadequately controlled by diet and exercise

Comparator

Placebo

Endpoint

Change in HbA1c from baseline to 40 weeks

Key result: Tirzepatide demonstrated robust reductions in HbA1c and body weight without increased risk of clinically significant hypoglycemia.

2023

OASIS 1 Trial

n = 667 · Lancet

Tested

Oral semaglutide 50 mg daily

Population

Adults with overweight or obesity without type 2 diabetes

Comparator

Placebo

Endpoint

Percentage change in body weight at week 68

Key result: High-dose oral semaglutide led to a superior weight loss of 15.1% compared to 2.4% with placebo.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis